These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8488751)

  • 1. Clinical, endocrine and neurochemical effects of moclobemide in depressed patients.
    Alevizos B; Hatzimanolis J; Markianos M; Stefanis CN
    Acta Psychiatr Scand; 1993 Apr; 87(4):285-90. PubMed ID: 8488751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
    Stefanis CN; Alevizos B; Markianos M; Hatzimanolis J
    J Neural Transm Suppl; 1988; 26():87-95. PubMed ID: 2452231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.
    Lensch K; Fuchs G; Böning J; Milech U
    Int Clin Psychopharmacol; 1987 Apr; 2(2):165-71. PubMed ID: 3298420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
    Markianos M; Alevizos B; Hatzimanolis J; Stefanis C
    Psychiatry Res; 1994 Jun; 52(3):259-64. PubMed ID: 7527564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moclobemide (Aurorix) in primary major depression.
    Rihmer Z; Barsi J; Vad G; György S; Zalay B; Vég K; Gábor A
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):367-72. PubMed ID: 8208985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.
    Williams R; Edwards RA; Newburn GM; Mullen R; Menkes DB; Segkar C
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):155-8. PubMed ID: 8468437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moclobemide (Ro 11-1163) versus imipramine in the treatment of depression.
    Casacchia M; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():43. PubMed ID: 2248067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants.
    Priest RG
    Acta Psychiatr Scand Suppl; 1990; 360():39-41. PubMed ID: 2248065
    [No Abstract]   [Full Text] [Related]  

  • 12. Moclobemide versus tranylcypromine in the treatment of depression.
    Rossel L; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():61-2. PubMed ID: 2248075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
    Bizière K; Berger M
    Acta Psychiatr Scand Suppl; 1990; 360():59-60. PubMed ID: 2248074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium.
    Botte L; Gilles C; Evrard JL; Mesters P; Wolfrum C; Berger M; Hellstern K; Ward J
    Acta Psychiatr Scand Suppl; 1990; 360():42. PubMed ID: 2248066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment dexamethasone suppression test as a predictor of response to phenelzine.
    Janicak PG; Pandey GN; Sharma R; Boshes R; Bresnahan D; Davis JM
    J Clin Psychiatry; 1987 Dec; 48(12):480-2. PubMed ID: 3693333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline.
    Kin NM; Nair NP; Amin M; Schwartz G; Ahmed SK; Holm P; Katona C; Kragh-Sorensen P; Klitgaard N; Song WY; West TE; Stage K
    Biol Psychiatry; 1997 Nov; 42(10):925-31. PubMed ID: 9359979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients.
    Monti JM
    Br J Psychiatry Suppl; 1989 Oct; (6):61-5. PubMed ID: 2619974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.
    Classen W; Laux G
    J Neural Transm Suppl; 1990; 32():185-8. PubMed ID: 2089088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DST urinary MHPG.SO4 excretion and platelet MAO activity in depression].
    Zhou DF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Oct; 18(5):274-8. PubMed ID: 3833511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.